Jay Lee

Company Reports

4568

Daiichi Sankyo Co Ltd

Daiichi Sankyo's World-Leading Antibody Drug Conjugate Platform Continues to Make Progress

Daiichi Sankyo's World-Leading Antibody Drug Conjugate Platform Continues to Make Progress

Jay Lee Apr 26, 2024
GETI B

Getinge AB Class B

Getinge’s Long-Term Story Intact but Near-Term Uncertainty Persists

Getinge’s Long-Term Story Intact but Near-Term Uncertainty Persists

Jay Lee Apr 2, 2024
TFX

Teleflex Inc

Teleflex Is Expanding Its Portfolio of Surgical and Interventional Devices

Teleflex Is Expanding Its Portfolio of Surgical and Interventional Devices

Jay Lee Mar 18, 2024
ERF

Eurofins Scientific SE

Eurofins Returning to Growth After a Challenging 2023

Eurofins Returning to Growth After a Challenging 2023

Jay Lee Feb 28, 2024
GH

Guardant Health Inc

Guardant Health, the Leader in Blood-Based Single Cancer Screening, Has a Long Way to Profitability

Guardant Health, the Leader in Blood-Based Single Cancer Screening, Has a Long Way to Profitability

Jay Lee Feb 26, 2024
WST

West Pharmaceutical Services Inc

West Pharmaceutical Facing Headwinds in 2024, but Long-Term Growth and Margin Expansion Story Intact

West Pharmaceutical Facing Headwinds in 2024, but Long-Term Growth and Margin Expansion Story Intact

Jay Lee Feb 16, 2024
ATR

AptarGroup Inc

Aptar's Profitability Improving due to Pharma Growth and Cost Controls

Aptar's Profitability Improving due to Pharma Growth and Cost Controls

Jay Lee Feb 9, 2024
4519

Chugai Pharmaceutical Co Ltd

Chugai's Cutting-Edge Antibody Platforms and Middle Molecule Programs Are Worth Watching

Chugai's Cutting-Edge Antibody Platforms and Middle Molecule Programs Are Worth Watching

Jay Lee Feb 2, 2024
SRT3

Sartorius AG Vorz-Inhaber-Akt ohne Stimmrecht

Sartorius AG Experiencing Tough 2023 Reset, but Long-Term Story Intact

Sartorius AG Experiencing Tough 2023 Reset, but Long-Term Story Intact

Jay Lee Nov 16, 2023
DIM

Sartorius Stedim Biotech SA

Sartorius Stedim Experiencing Tough 2023 Reset, but Long-Term Story Intact

Sartorius Stedim Experiencing Tough 2023 Reset, but Long-Term Story Intact

Jay Lee Nov 16, 2023
4502

Takeda Pharmaceutical Co Ltd

Takeda’s Pipeline Is Still Developing but Has Promise

Takeda’s Pipeline Is Still Developing but Has Promise

Jay Lee Oct 30, 2023
EXAS

Exact Sciences Corp

Exact Sciences' Cancer Screening Foothold Is Strong, but Liquid Biopsy Pipeline Not Derisked Yet

Exact Sciences' Cancer Screening Foothold Is Strong, but Liquid Biopsy Pipeline Not Derisked Yet

Jay Lee Oct 10, 2023
01177

Sino Biopharmaceutical Ltd

Sino Biopharmaceutical Has a Strong Sales Footprint, but Pipeline Needs More Differentiation

Sino Biopharmaceutical Has a Strong Sales Footprint, but Pipeline Needs More Differentiation

Jay Lee Jun 9, 2023

More About Jay Lee

Jay Lee is a senior equity analyst for Morningstar Asia Limited, a wholly owned subsidiary of Morningstar, Inc. He covers Chinese and Japanese healthcare companies.

Before joining Morningstar in 2017, Lee was an executive director and Asia head of mortgage products at Goldman Sachs, where he spent 11 years working on trading desks in New York, Tokyo, and Hong Kong.

Lee holds a bachelor’s degree in mathematics from Brown University.

Sponsor Center

How we make money

How we use your personal data

How we approach editorial content